Joseph Schwartz
Stock Analyst at Leerink Partners
(2.27)
# 1,457
Out of 4,412 analysts
114
Total ratings
33.05%
Success rate
0.26%
Average return
Main Sectors:
Top Industries:
31 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGLS Regulus Therapeutics | Initiates: Outperform | $6 | $2.42 | +147.93% | 2 | Mar 18, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Market Perform | $9 → $2 | $0.70 | +185.71% | 5 | Mar 14, 2024 | |
| APLT Applied Therapeutics | Initiates: Outperform | $12 | $4.28 | +180.37% | 1 | Feb 22, 2024 | |
| ANTX AN2 Therapeutics | Downgrades: Market Perform | $23 → $7 | $2.32 | +201.72% | 2 | Feb 13, 2024 | |
| SYBX Synlogic | Downgrades: Market Perform | $1 | $1.87 | -46.52% | 4 | Feb 9, 2024 | |
| RPHM Reneo Pharmaceuticals | Downgrades: Market Perform | $1 | $1.67 | -40.12% | 3 | Dec 15, 2023 | |
| DSGN Design Therapeutics | Downgrades: Market Perform | $6 | $3.78 | +58.73% | 4 | Aug 15, 2023 | |
| PTCT PTC Therapeutics | Initiates: Market Perform | $48 | $28.57 | +68.01% | 1 | Mar 17, 2023 | |
| PHVS Pharvaris | Maintains: Outperform | $20 → $18 | $23.35 | -22.91% | 5 | Feb 3, 2023 | |
| KALV KalVista Pharmaceuticals | Maintains: Outperform | $30 → $20 | $10.78 | +85.53% | 4 | Feb 3, 2023 | |
| IONS Ionis Pharmaceuticals | Maintains: Market Perform | $33 → $34 | $41.59 | -18.25% | 1 | Feb 3, 2023 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $122 → $130 | $80.91 | +60.67% | 8 | Feb 3, 2023 | |
| SRPT Sarepta Therapeutics | Reiterates: Outperform | $160 | $128.77 | +24.25% | 8 | Jan 20, 2023 | |
| ASND Ascendis Pharma | Maintains: Outperform | $148 → $163 | $135.90 | +19.94% | 13 | Jan 17, 2023 | |
| GOSS Gossamer Bio | Maintains: Outperform | $15 → $10 | $0.67 | +1,397.01% | 5 | Dec 7, 2022 | |
| SLDB Solid Biosciences | Maintains: Market Perform | $1 → $6 | $8.98 | -33.18% | 4 | Nov 10, 2022 | |
| PEPG PepGen | Maintains: Outperform | $40 → $33 | $11.93 | +176.61% | 2 | Nov 10, 2022 | |
| MREO Mereo BioPharma Group | Maintains: Outperform | $8 → $4 | $2.74 | +45.99% | 1 | Nov 10, 2022 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Outperform | $17 → $12 | $4.91 | +144.40% | 5 | Nov 4, 2022 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $115 → $108 | $44.24 | +144.12% | 5 | Nov 3, 2022 | |
| INSM Insmed | Maintains: Outperform | $52 → $50 | $24.80 | +101.61% | 3 | Oct 27, 2022 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $45 → $38 | $5.26 | +622.43% | 4 | Oct 20, 2022 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $36 → $39 | $42.12 | -7.41% | 1 | May 26, 2022 | |
| IFRX InflaRx | Maintains: Outperform | $6 → $4 | $1.33 | +200.75% | 3 | May 12, 2022 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $34 → $30 | $16.17 | +85.53% | 2 | May 12, 2022 | |
| RNA Avidity Biosciences | Maintains: Outperform | $53 → $50 | $24.36 | +105.25% | 3 | May 11, 2022 | |
| PTGX Protagonist Therapeutics | Maintains: Outperform | $50 → $30 | $25.15 | +19.28% | 5 | May 5, 2022 | |
| QURE uniQure | Maintains: Outperform | $71 → $56 | $4.53 | +1,136.20% | 1 | May 3, 2022 | |
| FOLD Amicus Therapeutics | Maintains: Outperform | $16 → $14 | $10.28 | +36.19% | 7 | Feb 24, 2022 | |
| FULC Fulcrum Therapeutics | Maintains: Outperform | n/a | $7.14 | - | 1 | Aug 13, 2021 | |
| PRQR ProQR Therapeutics | Maintains: Outperform | n/a | $1.94 | - | 1 | Sep 26, 2017 |
Regulus Therapeutics
Mar 18, 2024
Initiates: Outperform
Price Target: $6
Current: $2.42
Upside: +147.93%
Spruce Biosciences
Mar 14, 2024
Downgrades: Market Perform
Price Target: $9 → $2
Current: $0.70
Upside: +185.71%
Applied Therapeutics
Feb 22, 2024
Initiates: Outperform
Price Target: $12
Current: $4.28
Upside: +180.37%
AN2 Therapeutics
Feb 13, 2024
Downgrades: Market Perform
Price Target: $23 → $7
Current: $2.32
Upside: +201.72%
Synlogic
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.87
Upside: -46.52%
Reneo Pharmaceuticals
Dec 15, 2023
Downgrades: Market Perform
Price Target: $1
Current: $1.67
Upside: -40.12%
Design Therapeutics
Aug 15, 2023
Downgrades: Market Perform
Price Target: $6
Current: $3.78
Upside: +58.73%
PTC Therapeutics
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $28.57
Upside: +68.01%
Pharvaris
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $23.35
Upside: -22.91%
KalVista Pharmaceuticals
Feb 3, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $10.78
Upside: +85.53%
Ionis Pharmaceuticals
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $41.59
Upside: -18.25%
BioMarin Pharmaceutical
Feb 3, 2023
Maintains: Outperform
Price Target: $122 → $130
Current: $80.91
Upside: +60.67%
Sarepta Therapeutics
Jan 20, 2023
Reiterates: Outperform
Price Target: $160
Current: $128.77
Upside: +24.25%
Ascendis Pharma
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $135.90
Upside: +19.94%
Gossamer Bio
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $0.67
Upside: +1,397.01%
Solid Biosciences
Nov 10, 2022
Maintains: Market Perform
Price Target: $1 → $6
Current: $8.98
Upside: -33.18%
PepGen
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $11.93
Upside: +176.61%
Mereo BioPharma Group
Nov 10, 2022
Maintains: Outperform
Price Target: $8 → $4
Current: $2.74
Upside: +45.99%
Aurinia Pharmaceuticals
Nov 4, 2022
Maintains: Outperform
Price Target: $17 → $12
Current: $4.91
Upside: +144.40%
Ultragenyx Pharmaceutical
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $44.24
Upside: +144.12%
Insmed
Oct 27, 2022
Maintains: Outperform
Price Target: $52 → $50
Current: $24.80
Upside: +101.61%
Travere Therapeutics
Oct 20, 2022
Maintains: Outperform
Price Target: $45 → $38
Current: $5.26
Upside: +622.43%
Crinetics Pharmaceuticals
May 26, 2022
Maintains: Outperform
Price Target: $36 → $39
Current: $42.12
Upside: -7.41%
InflaRx
May 12, 2022
Maintains: Outperform
Price Target: $6 → $4
Current: $1.33
Upside: +200.75%
Edgewise Therapeutics
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $16.17
Upside: +85.53%
Avidity Biosciences
May 11, 2022
Maintains: Outperform
Price Target: $53 → $50
Current: $24.36
Upside: +105.25%
Protagonist Therapeutics
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $25.15
Upside: +19.28%
uniQure
May 3, 2022
Maintains: Outperform
Price Target: $71 → $56
Current: $4.53
Upside: +1,136.20%
Amicus Therapeutics
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $10.28
Upside: +36.19%
Fulcrum Therapeutics
Aug 13, 2021
Maintains: Outperform
Price Target: n/a
Current: $7.14
Upside: -
ProQR Therapeutics
Sep 26, 2017
Maintains: Outperform
Price Target: n/a
Current: $1.94
Upside: -